Gilead Sciences, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing medicines for life-threatening diseases. Their primary therapeutic areas are virology (including HIV, viral hepatitis, and COVID-19), oncology, and inflammatory diseases. Gilead operates in over 35 countries with headquarters in Foster City, California.

Gilead's key source of revenue in 2023 was from HIV treatments and prevention medications, such as Biktarvy, Genvoya, Descovy, and Odefsey. They also generate revenue from products for viral hepatitis (Epclusa, Vemlidy, Harvoni, Viread), COVID-19 (Veklury), oncology (Yescarta, Trodelvy, Tecartus), and other therapeutic areas (AmBisome, Letairis). Revenue is also generated through royalty agreements, collaborations, and other partnerships.

Gilead faces competition from other large pharmaceutical and biotechnology companies, as well as specialized and generic drug manufacturers. Competition is based on efficacy, safety, tolerability, pricing, and market access, among other factors.

• Employees: Approximately 18,000 (as of December 31, 2023)
• Geographic Footprint: Operates in more than 35 countries
• Headquarters: Foster City, California
• Founded: 1987
• Revenue: $27.1 billion (FY2023)
• Market Cap: $67.0 Billion (as of June 30, 2023)
• Key Subsidiaries/Brands: Asegua Therapeutics LLC, Kite

• CEO: Daniel P. O'Day
• CFO: Andrew D. Dickinson
• Chief Commercial Officer: Johanna Mercier
• Chief Medical Officer: Merdad V. Parsey, M.D., Ph.D.
• General Counsel: Deborah H. Telman
• Board Chair: Daniel P. O'Day

• Annual Revenue: $27.1 billion (FY2023)
• Net Income: $5.7 billion (FY2023)
• Market Cap: $67.0 billion (as of June 30, 2023)
• Total Assets: $62.1 billion (FY2023)
• Key Financial Highlights (FY2023):
  • Total revenue decreased 1% compared to FY2022 due to lower Veklury sales, offset by growth in HIV and oncology product sales.
  • Net income attributable to Gilead increased 23% compared to FY2022.

Gilead develops and commercializes therapies across various therapeutic areas, primarily focusing on antiviral medications. Key product categories and examples include:

• HIV: Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Stribild, Sunlenca (and others)
• Viral Hepatitis: Epclusa, Vemlidy, Harvoni, Viread
• COVID-19: Veklury (remdesivir)
• Oncology: Yescarta, Trodelvy, Tecartus
• Other: AmBisome, Letairis

Gilead also generates revenue through collaborations and partnerships, including revenue sharing from combination products and royalties for licenses of intellectual property.

Gilead operates as a single operating segment focused on the discovery, development, and commercialization of innovative medicines.

Gilead's business strategy focuses on developing and commercializing transformative therapies for areas of high unmet medical need, primarily in viral diseases, oncology, and inflammatory diseases. Key elements of their strategy include:

• Investing in internal R&D and pursuing external business development opportunities.
• Focusing on innovation and developing first-in-class therapies, improved treatment regimens, and enhanced drug delivery methods.
• Expanding the indications for existing products and developing new products to address unmet medical needs.
• Building strategic collaborations and partnerships to leverage external expertise and resources.
• Returning value to shareholders through dividends and share repurchases.

Gilead operates in the highly competitive biopharmaceutical industry. Key competitors include large pharmaceutical and biotechnology companies, specialized pharmaceutical firms, and generic drug manufacturers. The industry is subject to significant regulatory oversight, particularly from the FDA and comparable international agencies.

• Dependence on HIV Product Sales: A significant portion of Gilead's revenue comes from HIV products, making them vulnerable to market share loss from competing products or changes in treatment paradigms.
• Commercialization Challenges for Veklury: The demand for Veklury is tied to the prevalence and severity of COVID-19, creating uncertainty about future sales and potential inventory risks.
• Risks Associated with Cell Therapy: Gilead's cell therapies face challenges related to educating medical personnel, securing supplies, manufacturing complexities, and reimbursement.
• Drug Development Risks: The drug development process is inherently risky, with a high rate of failure and significant investments required.
• Competition: Gilead faces intense competition from other pharmaceutical and biotechnology companies, impacting pricing and market share.